HRT Financial’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-49,526
| Closed | -$2.91M | – | 3366 |
|
|
2023
Q4 | $2.91M | Buy |
+49,526
| New | +$2.78M | 0.02% | 494 |
|
|
2023
Q3 | – | Sell |
-73,276
| Closed | -$2.65M | – | 3336 |
|
|
2023
Q2 | $2.65M | Sell |
73,276
-8,030
| -10% | -$331K | 0.02% | 491 |
|
|
2023
Q1 | $3.02M | Buy |
+81,306
| New | +$3.66M | 0.04% | 426 |
|
|
2022
Q4 | – | Sell |
-3,830
| Closed | -$267K | – | 3416 |
|
|
2022
Q3 | $267K | Buy |
+3,830
| New | +$283K | ﹤0.01% | 2065 |
|
|
2022
Q1 | – | Sell |
-31,382
| Closed | -$4.6M | – | 4074 |
|
|
2021
Q4 | $4.6M | Buy |
+31,382
| New | +$4.87M | 0.03% | 318 |
|
|
2021
Q3 | – | Sell |
-118,131
| Closed | -$19.1M | – | 3905 |
|
|
2021
Q2 | $19.1M | Buy |
+118,131
| New | +$19M | 0.18% | 94 |
|
|
2021
Q1 | – | Sell |
-29,567
| Closed | -$6.49M | – | 3286 |
|
|
2020
Q4 | $6.49M | Buy |
+29,567
| New | +$6.39M | 0.13% | 126 |
|
|
2020
Q2 | – | Sell |
-11,508
| Closed | -$884K | – | 1821 |
|
|
2020
Q1 | $884K | Buy |
+11,508
| New | +$1.03M | 0.06% | 278 |
|
|
2019
Q4 | – | Sell |
-27,338
| Closed | -$2.13M | – | 1777 |
|
|
2019
Q3 | $2.13M | Buy |
+27,338
| New | +$2.57M | 0.1% | 158 |
|
Other funds holding MRTX
HRT Financial's MRTX Position: Q1 2024 in Review
HRT Financial sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 49,526 shares — an estimated $2.91M sold.
HRT Financial first reported a position in MRTX in Q3 2019 and held it in 9 quarters. The position peaked at $19.1M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- HRT Financial reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- HRT Financial sold 49,526 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.91M.
- HRT Financial first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
- HRT Financial's Mirati Therapeutics, Inc. Common Stock position peaked at $19.1M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on HRT Financial's 13F filing for Q1 2024, filed 13 May 2024.